Tag Archives: dyskinesia

H. Lundbeck A/S initiates a phase I study of a potential new treatment of Parkinson’s disease

Lu AF28996 is the third compound added to Lundbeck’s clinical development pipeline in 2018. VALBY, 28-Jun-2018 — /EuropaWire/ — H. Lundbeck A/S (Lundbeck) again expands its pipeline of clinical development projects with the initiation of a phase I study of a … Read the full press release

H. Lundbeck A/S to acquire Prexton Therapeutics BV for EUR 100 million upfront and up to EUR 805 million in development and sales milestones paid later

Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805 million in development, regulatory and sales milestones Foliglurax is a first-in-class treatment which entered clinical phase II testing in Parkinson’s … Read the full press release